Orbotech Ltd. (ORBK) Forms $53.21 Double Top; Natus Medical (BABY) Has 0.76 Sentiment

Orbotech Ltd. (ORBK) formed double top with $56.93 target or 7.00% above today’s $53.21 share price. Orbotech Ltd. (ORBK) has $2.55 billion valuation. The stock decreased 0.24% or $0.13 during the last trading session, reaching $53.21. About 57,799 shares traded. Orbotech Ltd. (NASDAQ:ORBK) has risen 49.39% since January 25, 2017 and is uptrending. It has outperformed by 32.69% the S&P500.

Natus Medical Incorporated provides newborn care and neurology healthcare services and products worldwide. The company has market cap of $937.69 million. It offers services and products used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. It currently has negative earnings. The companyÂ’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories.

Among 10 analysts covering Orbotech (NASDAQ:ORBK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Orbotech had 21 analyst reports since September 8, 2015 according to SRatingsIntel. Barclays Capital maintained Orbotech Ltd. (NASDAQ:ORBK) on Thursday, November 2 with “Overweight” rating. Jefferies maintained it with “Buy” rating and $42.0 target in Monday, September 11 report. Needham maintained the shares of ORBK in report on Tuesday, November 7 with “Buy” rating. The firm has “Buy” rating by Oppenheimer given on Thursday, August 10. The company was initiated on Tuesday, September 8 by Lake Street. The stock of Orbotech Ltd. (NASDAQ:ORBK) has “Buy” rating given on Monday, November 16 by Needham. Oppenheimer maintained the shares of ORBK in report on Wednesday, November 1 with “Buy” rating. The firm has “Overweight” rating given on Monday, December 21 by JP Morgan. Oppenheimer maintained it with “Outperform” rating and $35.0 target in Wednesday, December 2 report. The firm earned “Buy” rating on Thursday, August 3 by Oppenheimer.

Analysts await Orbotech Ltd. (NASDAQ:ORBK) to report earnings on February, 14. They expect $0.90 earnings per share, up 36.36% or $0.24 from last year’s $0.66 per share. ORBK’s profit will be $43.11 million for 14.78 P/E if the $0.90 EPS becomes a reality. After $0.86 actual earnings per share reported by Orbotech Ltd. for the previous quarter, Wall Street now forecasts 4.65% EPS growth.

Lyon Street Capital Llc holds 4.23% of its portfolio in Natus Medical Incorporated for 292,897 shares. Daruma Capital Management Llc owns 1.39 million shares or 3.24% of their US portfolio. Moreover, Beddow Capital Management Inc has 2.79% invested in the company for 158,480 shares. The New York-based Corsair Capital Management L.P. has invested 2.33% in the stock. Hillcrest Asset Management Llc, a Texas-based fund reported 239,089 shares.

The stock decreased 1.29% or $0.4 during the last trading session, reaching $30.6. About 36,100 shares traded. Natus Medical Incorporated (BABY) has risen 4.38% since January 25, 2017 and is uptrending. It has underperformed by 12.32% the S&P500.

Analysts await Natus Medical Incorporated (NASDAQ:BABY) to report earnings on February, 7. They expect $0.70 earnings per share, up 37.25% or $0.19 from last year’s $0.51 per share. BABY’s profit will be $21.45M for 10.93 P/E if the $0.70 EPS becomes a reality. After $0.40 actual earnings per share reported by Natus Medical Incorporated for the previous quarter, Wall Street now forecasts 75.00% EPS growth.